Serotonin augmentation therapy by escitalopram has minimal effects on amyloid-β levels in early-stage Alzheimer's-like disease in mice.

There was an almost significant reduction in the CSF ratio of Aβ42/Aβ40 in escitalopram-treated mice compared with vehicle-treated mice (escitalopram 0.20 ± 0.02, vehicle 0.23 ± 0.01) (Fig. 2b ).

also in 1,858 other papers